ImmunityBio (NASDAQ:IBRX - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $30.00 price objective on the stock.
Other equities research analysts have also recently issued research reports about the stock. BTIG Research began coverage on shares of ImmunityBio in a research note on Friday, January 10th. They issued a "buy" rating and a $6.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $8.00 target price on shares of ImmunityBio in a research report on Thursday, March 13th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $12.19.
Read Our Latest Analysis on IBRX
ImmunityBio Stock Down 5.7 %
Shares of NASDAQ IBRX traded down $0.17 during midday trading on Monday, reaching $2.80. 4,579,794 shares of the stock were exchanged, compared to its average volume of 5,601,650. The firm has a market cap of $2.39 billion, a price-to-earnings ratio of -3.06 and a beta of 0.82. The firm has a 50-day simple moving average of $3.12 and a two-hundred day simple moving average of $3.59. ImmunityBio has a twelve month low of $2.28 and a twelve month high of $10.53.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.11. The business had revenue of $7.55 million during the quarter, compared to analysts' expectations of $8.74 million. Research analysts expect that ImmunityBio will post -0.92 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Stephens Inc. AR acquired a new stake in shares of ImmunityBio in the fourth quarter valued at about $26,000. Cibc World Markets Corp purchased a new stake in ImmunityBio during the 4th quarter valued at about $35,000. Maia Wealth LLC acquired a new stake in ImmunityBio in the 4th quarter valued at about $37,000. GF Fund Management CO. LTD. purchased a new position in ImmunityBio in the 4th quarter worth approximately $37,000. Finally, Schechter Investment Advisors LLC acquired a new position in shares of ImmunityBio during the 4th quarter worth approximately $38,000. Hedge funds and other institutional investors own 8.58% of the company's stock.
About ImmunityBio
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Further Reading
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
